{"nctId":"NCT00091572","briefTitle":"Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)","startDateStruct":{"date":"2004-10-20","type":"ACTUAL"},"conditions":["Melanoma"],"count":859,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Temozolomide"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dacarbazine"]}],"interventions":[{"name":"Temozolomide","otherNames":["Temodal, Temodar, SCH 52365"]},{"name":"Dacarbazine","otherNames":["DTIC-Dome"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed, stage IV, surgically incurable melanoma\n* Age 18 years or older\n* World Health Organization (WHO) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Meets protocol requirements for specified laboratory values\n* Must be able to take oral medication\n* Must be disease free from cancer for period of 5 years (except for surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin).\n* Women of childbearing potential and men must be practicing a medically approved contraception.\n* Must provide written informed-consent to participate in the study.\n* Must have full recovery from major surgery or adjuvant treatment\n* No clinically uncontrolled infectious disease including HIV or AIDS-related illness\n\nExclusion Criteria:\n\n* Ocular melanomas\n* Brain Metastases\n* Prior cytokine or chemotherapy for stage IV disease\n* Pregnant or nursing women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Progression Free Survival","description":"Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":null},{"groupId":"OG001","value":"2.17","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival","description":"Overall Survival was defined as the time from the date of randomization to the date of death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.13","spread":null},{"groupId":"OG001","value":"9.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate in Subjects With Measurable Lesions","description":"Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Objective Response","description":"Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.34","spread":null},{"groupId":"OG001","value":"8.31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":124,"n":419},"commonTop":["FATIGUE","NAUSEA","VOMITING","CONSTIPATION","ANOREXIA"]}}}